Flagship Ventures is a venture capital firm focused on creating, financing, and building innovative companies. Founded in 1999, Flagship manages more than $500 million in early-stage funds and operates from its offices at Kendall Square in Cambridge, MA. With an active portfolio of more than 40 companies, the firm's strategy is to balance its investments across three principal business sectors: Therapeutics, Life Science Tools & Diagnostics, and BioEnergy/Cleantech. During the past two decades, Flagship's principals have been involved as founders or investors in many highly successful ventures, including Adnexus Therapeutics, Alere Medical, Aspect Medical, Celera Genomics, ChemGenics Pharmaceuticals, Color Kinetics, Cytyc, DataSage, Exact Sciences, Helicos Biosciences, Hypnion, IDEXX, Morphotek, PerSeptive Biosystems, and TripAdvisor.
NanoDimension is a venture capital firm committed to building companies developing market-disruptive technologies on the nano scale. Founded in 2002, and with offices in Europe and the United States, NanoDimension focuses on early to mid-stage investments across business sectors.
New Enterprise Associates
New Enterprise Associates, Inc. (NEA) is a leading venture capital firm focused on helping entrepreneurs create and build major new enterprises that use technology to improve the way we live, work, and play. Since its founding in 1978, the firm has followed the same core principles: Supporting its entrepreneurs, providing an excellent return to its limited partners, and practicing its profession with the highest standards and respect. Through its affiliated funds, NEA focuses on investments at all stages of a company’s development, from seed stage through IPO. With approximately $8.5 billion in committed capital, NEA’s experienced management team has invested in more than 650 companies, of which more than 160 have gone public and more than 250 have been acquired. NEA has U.S. offices in Chevy Chase, Maryland; Menlo Park, California; and Baltimore, Maryland. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China.
Novo A/S, the holding company in the Novo Group, is responsible for the management of the assets of the Novo Nordisk Foundation, which are currently valued at more than DKK 300 billion.
Novo A/S is a private limited liability company fully owned by the Novo Nordisk Foundation.
Besides being the major shareholder in the Novo Group companies, Novo A/S provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies, within life science, as well as manages a broad portfolio of financial assets.
For further information visit www.novo.dk
TaiAn Technologies is both a biotechnology service company that helps transfer breakthrough biotech/biomedical technologies into Taiwan and a management company for biotechnology venture capital funds. TaiAn manages two dedicated life sciences and healthcare funds, Eminent Venture Capital Fund and Eminent II Venture Capital Fund. The group's current investment focus includes pharmaceuticals, biopharmaceuticals, medical devices, diagnostic products, and medical instruments, engaging with companies that have strong value propositions for products.
Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $1.9 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, nearly 50 Versant companies have achieved successful acquisitions or IPOs.